Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously.
This study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg/m² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once weekly, mazdutide 6 mg once weekly, or placebo once weekly. All participants also receive standardized diet and exercise guidance throughout the study.
Treatment lasts 24 weeks, followed by 24 weeks of off-drug follow-up to see whether any benefits are maintained. The main question is: what proportion of participants achieve completely normal blood sugar (normal HbA1c, fasting glucose, AND glucose tolerance test) after 24 weeks of treatment? The study is conducted at approximately 10 hospitals across China.

开始日期2026-07-01

申办/合作机构

山东华升医院有限公司

[+1]

NCT07657676

/ Not yet recruiting临床4期IIT

Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial

This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NAF PET/CT imaging.

开始日期2026-05-25

申办/合作机构

国家心血管病中心

NCT07469800

/ Recruiting临床3期

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Participants With Mild to Moderate Hypertension Complicated by Overweight/Obesity Who Have Not Received Antihypertensive Drug Treatment

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment

开始日期2026-04-23

申办/合作机构

信达生物制药（苏州）有限公司

100 项与玛仕度肽相关的临床结果

登录后查看更多信息

100 项与玛仕度肽相关的转化医学

登录后查看更多信息

100 项与玛仕度肽相关的专利（医药）

登录后查看更多信息

项与玛仕度肽相关的文献（医药）

2026-05-04·EXPERT OPINION ON THERAPEUTIC PATENTS

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes

Review

作者: Abdul Fasi, Mohammed

INTRODUCTION:

Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined.

AREAS COVERED:

This review presents a comprehensive patent landscape analysis of mazdutide and related oxyntomodulin analogs. Patent documents were identified using the Patentscope database, covering filings between 2015 and 2025. Twelve patent families were analyzed, encompassing composition-of-matter, process chemistry, formulation technologies, dosing regimens, and therapeutic applications. The analysis traces the evolution of innovation from early peptide design by Eli Lilly to later formulation, clinical, and indication-expansion strategies led by Innovent Biologics, including obesity, type 2 diabetes, hyperuricemia, and adolescent obesity.

EXPERT OPINION:

Mazdutide illustrates how layered patent strategies integrating molecular design, manufacturability, formulation stability, and clinical use claims can secure durable exclusivity. This approach provides a strategic model for future dual and multi-receptor peptide therapeutics.

2026-05-01·Lancet Diabetes & Endocrinology

Beyond weight loss: multisystem benefits of obesity medications

Review

作者: van Rossum, Elisabeth F C ; Savas, Mesut ; Kuckuck, Susanne ; Boon, Mariëtte R

Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions. This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin). We evaluated the effects of obesity medications across major obesity-related conditions, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnoea syndrome, polycystic ovary syndrome (recently named polyendocrine metabolic ovarian syndrome), osteoarthritis, muscle mass, depression, quality of life, and food cravings, along with binge-eating disorders, substance use disorders, and neurodegenerative diseases. Overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions. While many benefits of obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with GLP-1 receptor agonist-based therapies. A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.

2026-05-01·Med

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial

Article

作者: Zhang, Yawei ; Ma, Qingyang ; Wang, Yanqi ; Cheng, Zhifeng ; Pang, Shuguang ; Ji, Linong ; Du, Haiwei ; Liu, Zihan ; Qian, Lei ; Han-Zhang, Han ; Li, Xiaoli ; Deng, Huan ; Qiu, Wei ; Jiang, Hongwei

BACKGROUND:

Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity.

METHODS:

In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m² and without diabetes were randomized 3:1 to receive mazdutide 9 mg or placebo for 24 weeks. The primary endpoint was the percentage change in body weight from baseline to week 24.

FINDINGS:

Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20). At week 24, the mean percentage change in weight from baseline was -12.78% with mazdutide 9 mg and 1.80% with placebo (treatment difference: -14.58% [95% confidence interval (CI) -18.00, -11.16], p < 0.0001). Weight reduction ≥5% was achieved by 81.7% of participants with mazdutide after 24-week treatment, while no participants with placebo achieved this threshold. Mazdutide treatment was associated with greater improvements in cardiometabolic risk factors vs. placebo. The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity.

CONCLUSIONS:

Mazdutide 9 mg was safe and led to substantial weight reductions in Chinese adults with a BMI ≥ 30kg/m² but without diabetes after 24-week treatment. These results support further clinical development of mazdutide 9 mg for the treatment of obesity.

FUNDING:

This study was sponsored by Innovent Biologics.

3,178

项与玛仕度肽相关的新闻（医药）

2026-07-16

·BioBAY

全国医药工业百强！BioBAY孵化企业信达生物杀入全国医药工业TOP26

近日，在2026年（第43届）全国医药工业信息年会上，“2025年度中国医药工业主营业务收入前100位企业”（医药工业百强）正式揭晓。由BioBAY精心培育孵化的标杆企业——信达生物制药（苏州）有限公司，凭借卓越的营收表现与强劲的成长势头荣耀入选，位列第26位，排名较上一年度大幅跃升15位，展现出令人瞩目的发展速度。这一成绩不仅是信达生物自身实力的体现，更是BioBAY作为创新孵化平台培育能力的生动注脚。 01 排名跃升15位，信达生物彰显创新药企成长速度信达生物此次排名较上年跃升15位至第26位，在前50强企业中上升幅度位居前列。这一成绩的背后，是公司长期坚持创新驱动战略的成果。2025年，信达生物产品收入首次突破百亿元，围绕肿瘤与综合产品线的“双轮驱动”结构持续推进产品梯队建设，以成熟的研发体系、重磅管线布局与强劲的商业化表现，代表中国创新药第一梯队成功跻身行业领导阵营。信达生物成立于2011年，自创立之初便秉持“开发出老百姓用得起的高质量生物药”的使命，致力于肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物研发、生产和销售。目前，公司已有19个产品获批上市，包括明星产品信迪利单抗（达伯舒®）、贝伐珠单抗（达攸同®）、玛仕度肽注射液（信尔美®）、替妥尤单抗N01注射液（信必敏®）、托莱西单抗注射液（信必乐®）、匹康奇拜单抗注射液（信美悦®）等，覆盖多个治疗领域。在研管线方面，信达生物持续发力，现有5个新药分子已进入III期或关键性临床研究，另有14个品种已进入临床阶段，形成了梯队完备、后劲十足的产品矩阵。在国际合作层面，信达生物凭借卓越的研发能力和质量体系，已与礼来、罗氏、武田、赛诺菲等全球知名药企达成30多项战略合作，成为中国创新药“走出去”与“引进来”的典范。在谋求自身发展的同时，公司始终心系患者，患者援助项目累计惠及20余万普通患者，药物捐赠总价值超40亿元人民币，以实际行动践行“以患者为中心”的承诺。正是这种“创新+可及”的双轮驱动，让信达生物在研发投入上持续领跑——公司曾位居“中国医药工业研发强度工业企业”十强榜首，此次百强榜单排名的大幅跃升，正是其高强度研发投入转化为商业化成果的有力证明。 02 BioBAY孵化赋能，创新沃土孕育行业标杆信达生物从BioBAY孵化成长，现已发展成为市值突破1500亿的港股医药板块龙头企业。此次入选百强榜单，不仅是信达生物自身发展的重要里程碑，更是BioBAY作为国内生物医药创新高地孵化能力的集中体现。在创新药领域，BioBAY已集聚相关企业超680家，涌现出一批代表中国创新药第一梯队的行业领军企业。BioBAY通过搭建公共技术平台、链接资本资源、优化政策服务，为企业全生命周期成长持续赋能，信达生物正是这一培育体系结出的璀璨硕果。当前，我国医药行业仍处于深度调整期，百强企业整体收入连续四年呈回调态势，但行业研发投入持续攀升。2025年百强企业平均研发费用达8.4亿元，同比增长1.5%，再创新高。信达生物在此背景下实现排名大幅跃升，展现出创新药企穿越周期、逆势增长的强劲韧性，也印证了BioBAY培育模式的战略价值。展望未来，信达生物将继续秉持“始于信，达于行”的初心，以创新为引擎，以研发为驱动，加速全球化布局，为更多患者带来可及可负担的高质量生物药。而BioBAY也将持续深耕创新生态，培育更多像信达生物这样的行业标杆，为中国生物医药产业的高质量发展贡献更多力量。撰稿：徐悦责编：于嘉敏审核：任旭推荐阅读 11亿美元！信达生物CD40L单抗出海 18家企业入选潜在独角兽榜单！BioBAY持续领跑生物医药产业创新再添殊荣！BioBAY入驻企业吉美瑞生斩获2026年WIPO全球奖

2026-07-16

·同写意

瑞孚迪携多肽药物全流程研发解决方案，邀您相约大国新药多肽专场共促未来！

继小分子、单抗之后，多肽药物凭借高特异性、低毒副作用、兼具口服/长效改造潜力，成为代谢、心血管、纤维化、肿瘤四大赛道最热研发风口之一，全球与国内在研管线迎来全面扩容。代谢慢病多肽：GLP-1多靶点赛道持续迭代单靶点GLP-1：司美格鲁肽已落地肥胖、糖尿病、心血管保护适应症，并于7月9日正式发布将纳入2026国家基本药物目录（仅针对2型糖尿病适应症）。国内单靶点GLP-1多肽创新管线布局丰富，给药周期持续拉长、口服路线同步突破。双/三受体激动剂：全球GLP-1多靶点多肽中，礼来替尔泊肽是已上市GLP--1/GIP双靶点标杆，减重降糖疗效显著优于单靶点司美格鲁肽；信达与礼来合作玛仕度肽为GLP-1/GCGR双靶点代表，在脂肪肝领域优势突出；礼来Retatrutide是现阶段临床进展最快的GLP-1/GIP/GCGR三靶点长效多肽，依托胰高血糖素受体通路提升全身能量消耗、加速肝脏脂质分解，80周关键III期临床平均减重幅度突破28%，创下当前注册类减重药物最优临床数据，是下一代代谢多肽的标杆性在研分子。降脂抗动脉粥样硬化：靶向PCSK9口服大环肽 Enlicitide（默沙东）：全球唯一进入III期口服大环肽PCSK9抑制剂，通过环化+脂肪酸修饰抵抗消化道降解，每日口服；机制为竞争性阻断PCSK9与LDL受体结合，恢复肝脏清除胆固醇能力。三项CORALreef III期全部阳性，他汀联用下调LDL-C 55%–61.5%，同步降低ApoB、Lp（a），疗效对标注射PCSK9单抗，无注射痛苦、免疫原性更低，2026年计划递交上市申请，填补口服长效降脂多肽空白，大幅降低心梗、脑梗远期风险。心衰、抗纤维化：利钠肽家族、IL-11靶向多肽利钠肽类多肽为心衰领域核心治疗药物，已上市重组人脑利钠肽用于急性失代偿性心衰静脉干预，多款国产仿制药完成III期临床开发；长效多肽Cenderitide整合ANP、CNP双重利钠肽通路，兼具平稳降压与抗心肌纤维化活性。靶向IL-11多肽开辟心血管纤维化创新治疗方向，对比存在全身毒副作用的TGF-β抑制剂，可特异性阻滞心肌、血管成纤维细胞异常活化。 PDC（多肽药物偶联物） PDC依托小分子靶向多肽替代抗体，相较ADC具备分子量更小、实体瘤穿透性更强、免疫原性低、化学合成成本可控等优势，已成为靶向抗肿瘤多肽前沿赛道；海外已有¹⁷⁷Lu-DOTATATE等产品获批，多款靶向SSTR2的PDC推进至II/III期并展现可观客观缓解率，AI辅助设计、环肽靶向、双特异性多肽偶联、双载荷PDC等新技术持续迭代。重磅一同写意《大国新药》多肽药物研发前沿专场重磅开启国内多肽创新管线百花齐放，技术路线百花争鸣，行业亟需平台互通、经验共鉴、资源对接。同写意《大国新药》特设多肽药物研发前沿专场，联合瑞孚迪（Revvity）共同主办，定于7月23日下午重磅开讲。本场汇聚国内多肽产业全链条领军企业创始人、研发负责人、CMC专家、资本投资人，围绕GLP-1迭代、环肽筛选、小型偶联药物、多肽一体化开发、AI设计、国产多肽出海机遇等核心议题深度分享，圆桌对话直击行业研发痛点、全球化发展机遇与落地挑战，覆盖从早期靶点筛选到临床转化全产业链干货。 CPIC大国新药会议信息会议时间：2026年7月22日-24日会议地点：上海国家会展中心 4.2H馆上海市徐泾镇松泽大道333号，出租车定位7号门瑞孚迪展位号：B25 多肽药物研发前沿专场：7月23日 13:30-17:00 展厅：C2 会议日程如下，欢迎业内人士到场交流！多肽药物研发前沿专场 Peptide Drug R&D Frontier Session 联合主办：瑞孚迪 Co-Organizer:Revvity 13:30-14:00 GLP-1研发历程与展望 GLP-1 R&D Journey and Outlook 王庆华：银诺医药创始人、董事长、CEO Wang Qinghua: Founder, Chairman&CEO, Guangzhou Innogen Pharmaceutical Group Co., Ltd. 14:00-14:20 抗肿瘤分子精准递送 Precise delivery of anti-tumor molecules 苏长青：复星万邦集团药物研究院首席科学家 Changqing Su: Chief Scientist, Pharmaceutical Research Institute, Fosun Wanbang Group 14:20-14:40 mRNA展示与AI相结合的环肽发现 Cyclic Peptide Discovery Integrating mRNA Display and Al 崔海峰：海量药科CSO Cui Haifeng: CSO, Shanghai Highline Therapeutics, Inc. 14:40-15:00 小型偶联药物的近期研发进展和临床探索 Recent R&D trends and clinical progresses of small format drug conjugates 邵军：同宜医药CTO、CO0 Jun Shao: Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co. 15:00-15:20 一体化CMC平台加速多肽药物发现与开发 Integrated CMC Solutions to accelerate Peptide Drug Discovery and Development 方国永：药明康德副总裁、WuXi TIDES寡核苷酸和多肽药物开发负责人 William Fang: Vice President, Head of Oligonucleotide & Peptide Development, WuXi TIDES 15:20-15:40 休息 Break 15:40-16:00 AI精准设计环肽药物，攻克不可成药靶点 Al-Designed Cyclic Peptide Drugs to Tackle Undruggable Targets 张根卫：品泰科技多肽研发负责人 Zhang Genwei: Peptide R&D Lead, XtalPi Holdings Limited 16:00-16:20 GLP-1到多靶点激动剂的多肽药物筛选与评价 Screening and Evaluation of Peptide Drugs from GLP-1 to Multi-target Agonists 王心媛：瑞孚迪中国应用业务技术经理 Wang Xinyuan: FAS Manager, China Application, Rewvity 16:20-17:00 圆桌对话：中国多肽创新药走向全球--机会、挑战与未来 Roundtable: China's Innovative Peptide Drugs Going Global -Opportunities, Challenges, and the Future 刘疆（主持）：瑞孚迪全球副总裁、大中华区总经理 Liu Jiang(Moderator): Vice President & General Manager, Greater China, Revvity 曹春来：联邦生物CEO Cao Chunlai: CEO, Federal Biotechnology (Zhuhai Hengqin) 刘春光：泰珑投资管理合伙人 Chunguang Liu: Managing Partner, Tailong VC 邵军：同宜医药CTO、CO0 Jun Shao: Chief Technology Officer (CTO), Coherent Biopharma (Suzhou) Co. 陈小新：众生药业副总裁，众生睿创联合创始人、董事长&CEO Chen Xiaoxin: Vice President, Guangdong Zhongsheng Pharmaceutical; Co-Founder, Chairman & CEO, Guangdong Zhongsheng Ruichuang Biological Technology 张英俊：东阳光药董事长 Zhang Yingjun: Chairman, Sunshine Lake Pharma 徐文洁：银诺医药高级副总裁、首席商务官 Wenjie Xu: Senior Vice President Chief Commercial Officer,Innogen 上下滑动查看会议日程详情重磅二瑞孚迪全新多肽药物研发解决方案正式发布瑞孚迪全新推出多肽药物全流程研发解决方案，一站式覆盖多肽药物从先导分子筛选、蛋白互作验证、内化评估、细胞通路功能评价等多元场景，扫描下方二维码，即可获取，了解精彩详情！即日起扫描下方二维码预报名，可于瑞孚迪展位现场领取Rebobo耳机包一个，数量有限，先到先得！参考文献 1. Coskun, Tamer et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Molecular metabolism vol. 18 (2018): 3-14. doi:10.1016/j.molmet.2018.09.009 2. Hoeg-Jensen, Thomas et al. “Glucose-sensitive insulin with attenuation of hypoglycaemia.” Nature vol. 634,8035 (2024): 944-951. doi:10.1038/s41586-024-08042-3 3. Lear, Sam et al. “De novo discovery of cyclic peptide inhibitors of IL-11 signaling.” Bioorganic & medicinal chemistry vol. 119 (2025): 118017. doi:10.1016/j.bmc.2024.118017 4. Coskun, Tamer et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell metabolism vol. 34,9 (2022): 1234-1247.e9. doi:10.1016/j.cmet.2022.07.013 .

2026-07-15

·今日头条

这个概念很火爆——减肥药

大A减肥药概念最近很火，其核心是围绕 GLP-1 受体激动剂类创新药及全产业链的投资主题，区别于普通减肥保健品、代餐等消费类产品，是创新药赛道中兼具医疗属性与消费属性的重磅细分领域。 GLP-1 类药物最初用于 2 型糖尿病治疗，后续临床证实其具备显著的减重效果，通过抑制食欲、延缓胃排空、调节能量代谢实现体重控制，且安全性远优于传统减重药物，是当前全球医学验证的主流减重方案。减重药的技术演进围绕「靶点升级、剂型优化、效果提升」三条主线推进，当前已形成清晰的代际梯队：代际靶点类型代表产品减重幅度产业定位第一代 GLP-1 单靶点利拉鲁肽、司美格鲁肽 10%~15% 当前市场主流，仿制药竞争主战场第二代双靶点激动剂（GLP-1/GIP、GLP-1/GCGR）替尔泊肽、玛仕度肽 15%~20% 国产创新药核心突破方向，临床效果显著优于单靶点第三代三靶点激动剂（GLP-1/GIP/GCGR）全球多处于临床阶段有望突破 20% 长期技术迭代方向，进一步打开减重上限 GLP-1 类药物的价值远不止于减重，正在向更广泛的代谢疾病领域延伸：已验证的有2型糖尿病、肥胖 / 超重；临床推进中的有非酒精性脂肪肝（NASH）、慢性心衰、睡眠呼吸暂停、慢性肾病等，持续打开市场天花板。 “减肥药”上下游产业链 1. 上游：原料与配套多肽原料与耗材：氨基酸原料、固相合成树脂、纯化填料，是多肽药物规模化生产的核心配套，高端品类曾长期依赖进口； CDMO/CMO 服务：承接药企的多肽药物工艺开发与定制生产，是产能释放的核心载体；药用配套：注射笔、特种针头、药用包装、辅料。 2. 中游：药物研发与生产创新药企业：自主研发多靶点创新药，依靠临床数据与差异化竞争，具备长期成长逻辑；仿制药企业：快速跟进成熟品种，依靠成本与渠道优势抢占市场，是短期商业化兑现的主力。 3. 下游：商业化渠道医疗机构：处方核心渠道，覆盖病理性肥胖人群；零售药房与线上医疗：院外市场主力，承接消费级减重需求；医美机构、体重管理服务：消费场景延伸，提升产品可及性。减肥药行业逻辑当前全球减重药市场由两家欧美药企主导，技术与商业化全面领先，合计占据 90% 以上市场份额：诺和xx：司美格鲁肽（Wegovy）全球减重药龙头，新一代胰淀素双靶点药物处于临床后期；礼xx：替尔泊肽（双靶点）减重效果更优，口服小分子奥氟格列隆率先获批，管线迭代速度领先。国内呈现仿制药放量、创新药突破，多层次梯队成型。GLP-1 赛道处于 “仿制药集中落地、创新药快速追赶” 的阶段，已形成清晰的竞争梯队：第一梯队：原研创新龙头依靠自主研发的差异化靶点实现临床数据突破，具备长期竞争力：信达xx：玛仕度肽（GLP-1/GCGR 双靶点）已上市，是国内首款自主研发的原研双靶点减重药，头对头数据显著优于司美格鲁肽，2026 年销售目标 18 亿元，国产减重药销售额第一；恒瑞xx：双靶点激动剂 HRS9531 减重适应症上市申请已获受理，口服小分子 GLP-1 同步推进至 Ⅲ 期临床；先为xx：埃诺格鲁肽 2026 年 3 月获批肥胖适应症，为全球首个 cAMP 偏向型 GLP-1 受体激动剂。第二梯队：仿制药主力企业聚焦成熟品种的首仿与快速跟进，是短期商业化兑现的核心：华东xx：利拉鲁肽减重适应症国内首仿获批，司美格鲁肽仿制药申报中，同时布局双靶点创新药与口服管线，是国内减重药商业化布局最完善的企业；丽珠xx、复星xx、常山xx：司美格鲁肽仿制药或长效 GLP-1 处于审评或临床后期，2026-2027 年集中落地。第三梯队：上游配套与CDMO行业景气度的 “卖铲人”，订单随全行业产能扩张同步放量：CDMO：凯xx、博腾xx、普洛xx，承接全球与国内多肽药物订单；原料与耗材：诺泰生物、圣诺生物（多肽原料药）、蓝晓科技（纯化填料）。

100 项与玛仕度肽相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	中国	信达生物制药（苏州）有限公司	2025-09-16
肥胖	中国	信达生物制药（苏州）有限公司	2025-06-24
超重	中国	信达生物制药（苏州）有限公司	2025-06-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血压	临床3期	中国	信达生物制药（苏州）有限公司	2026-03-20
阻塞性睡眠呼吸暂停综合征	临床3期	中国	信达生物制药（苏州）有限公司	2025-05-13
代谢功能障碍相关的脂肪肝病	临床3期	中国	信达生物制药（苏州）有限公司	2025-04-22
早发性 II 型糖尿病	临床3期	中国	信达生物制药（苏州）有限公司	2024-02-29
代谢功能障碍相关脂肪性肝炎	临床2期	中国	信达生物制药（苏州）有限公司	2025-06-20
射血分数中等的心力衰竭	临床2期	中国	信达生物制药（苏州）有限公司	2025-04-01
射血分数保留型心力衰竭	临床2期	中国	信达生物制药（苏州）有限公司	2025-04-01
射血分数降低的心力衰竭	临床2期	中国	信达生物制药（苏州）有限公司	2025-04-01
高尿酸血症	临床前	中国	信达生物制药（苏州）有限公司	2023-07-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06164873 (GLORY-2, ADA2026)	临床3期	肥胖	462	Mazdutide 9 mg	繭鹽鹹糧築鹽積鏇膚網(糧選獵顧淵襯鏇範醖製) = 壓窪鏇齋選壓構廠餘遞壓範簾製糧淵憲蓋選夢 (製築窪淵齋鬱鏇遞網選 ) 更多	积极	2026-06-20
				Placebo	繭鹽鹹糧築鹽積鏇膚網(糧選獵顧淵襯鏇範醖製) = 糧鏇選夢窪築遞壓糧積壓範簾製糧淵憲蓋選夢 (製築窪淵齋鬱鏇遞網選 ) 更多
NCT04904913 (Pubmed \| Med)	临床2期	肥胖	80	Mazdutide 9 mg	構鏇繭範襯觸淵憲壓鏇(膚廠艱鬱憲簾蓋糧獵選) = 艱鏇壓壓窪窪鏇衊鑰構衊積遞蓋獵製窪鏇淵膚 (醖糧積構簾淵憲積鹽窪 ) 更多	积极	2026-05-01
				Placebo	構鏇繭範襯觸淵憲壓鏇(膚廠艱鬱憲簾蓋糧獵選) = 鏇積觸遞淵夢鏇繭願繭衊積遞蓋獵製窪鏇淵膚 (醖糧積構簾淵憲積鹽窪 )
NCT06124807 (CTgov)	临床2期	超重 \| 肥胖	179	Placebo (Placebo)	築繭鹹夢糧衊願顧壓構(齋蓋鹹選構醖遞衊艱繭) = 顧製齋艱鏇鑰鹽獵憲壓鬱鬱淵構襯築醖鹽衊觸 (窪衊網襯網鹽憲淵蓋繭, 0.787) 更多	-	2026-04-21
				Mazdutide (10 mg Mazdutide)	築繭鹹夢糧衊願顧壓構(齋蓋鹹選構醖遞衊艱繭) = 鹽簾鬱獵鹽築憲製醖繭鬱鬱淵構襯築醖鹽衊觸 (窪衊網襯網鹽憲淵蓋繭, 0.744) 更多
NCT05606913 (DREAMS-2, Nature \| Pubmed \| PRNewswire) 人工标引	临床3期	2型糖尿病	731	Mazdutide 4 mg	願遞糧衊繭衊築簾糧廠(憲淵艱鏇夢糧鏇獵糧壓) = 繭艱淵齋繭鏇積積夢艱網鏇獵網壓鹽觸鹽願鏇 (遞範廠鹽憲壓鬱齋選膚 ) 达到更多	优效	2025-12-17
				Mazdutide 6 mg	願遞糧衊繭衊築簾糧廠(憲淵艱鏇夢糧鏇獵糧壓) = 鑰餘獵壓夢鹽構鏇膚壓網鏇獵網壓鹽觸鹽願鏇 (遞範廠鹽憲壓鬱齋選膚 ) 达到更多
NCT05628311 (DREAMS-1, Nature \| Pubmed \| PRNewswire) 人工标引	临床3期	2型糖尿病	320	Mazdutide 4 mg	淵廠糧蓋糧鹽觸蓋選夢(襯願艱壓繭選廠壓襯獵) = 蓋鹹鬱餘鹹繭餘鹹願簾醖醖簾繭衊範鬱齋淵蓋 (簾壓鏇鏇構製製襯艱壓 ) 达到更多	积极	2025-12-17
				Mazdutide 6 mg	淵廠糧蓋糧鹽觸蓋選夢(襯願艱壓繭選廠壓襯獵) = 齋鹽簾製鹽築顧壓艱獵醖醖簾繭衊範鬱齋淵蓋 (簾壓鏇鏇構製製襯艱壓 ) 达到更多
NCT05606913 (Pubmed \| Nature)	临床3期	2型糖尿病	731	Mazdutide 4 mg	遞齋獵製範衊網窪衊顧(範鏇獵獵淵鹹壓艱簾網) = The most common treatment-emergent adverse events were diarrhoea, nausea and vomiting. 顧範選鹽齋構鬱簾襯鏇 (簾鹽獵壓網積鑰窪觸觸 )	积极	2025-12-17
				Mazdutide 6 mg
PRNewswire 人工标引	临床1期	肥胖	36	mazdutide 4 mg	築齋鹹醖鬱襯選蓋願艱(膚膚壓選餘醖淵簾衊遞) = 網網遞淵艱廠獵鑰製蓋網製構廠襯鹽糧壓鹹齋 (遞顧齋願窪構齋壓蓋製 ) 达到更多	积极	2025-12-11
				mazdutide 6 mg	築齋鹹醖鬱襯選蓋願艱(膚膚壓選餘醖淵簾衊遞) = 艱觸網齋蓋齋積廠夢餘網製構廠襯鹽糧壓鹹齋 (遞顧齋願窪構齋壓蓋製 ) 达到更多
NCT06164873 (GLORY-2, Company_Website) 人工标引	临床3期	肥胖	462	Mazdutide 9 mg	夢鑰壓餘範簾艱餘範膚(襯構範廠窪餘窪網餘構) = 糧觸艱築餘蓋餘顧憲醖遞觸鬱鹹醖膚鏇築積衊 (築遞餘齋積製鏇廠蓋鬱 ) 达到更多	积极	2025-11-20
				Placebo	夢鑰壓餘範簾艱餘範膚(襯構範廠窪餘窪網餘構) = 窪衊夢醖構鏇遞膚齋築遞觸鬱鹹醖膚鏇築積衊 (築遞餘齋積製鏇廠蓋鬱 ) 达到更多
NCT05623839 (Pubmed \| Diabetes Obes Metab)	临床1期	超重 \| 肥胖	32	Mazdutide (Cohort 1)	鹽鏇廠範網遞網膚鏇膚(廠醖艱廠夢壓範選簾憲) = the most common AEs were mild or moderate gastrointestinal disorders. 繭築襯廠積網窪鹽齋糧 (憲顧觸膚鹽醖廠餘鏇願 )	积极	2025-11-01
				Mazdutide (Cohort 2)
NCT06184568 (DREAMS-3, PRNewswire) 人工标引	临床3期	2型糖尿病	349	mazdutide 6 mg	範製範積積衊蓋醖鏇壓(窪簾襯糧繭鹽觸鬱壓襯) = 糧糧築繭窪壓製鹹簾廠獵繭選築糧齋選積鹹蓋 (壓鹹醖簾願簾齋廠糧糧 ) 达到更多	积极	2025-10-26
				semaglutide 1 mg	範製範積積衊蓋醖鏇壓(窪簾襯糧繭鹽觸鬱壓襯) = 艱製糧選鹹醖簾窪遞遞獵繭選築糧齋選積鹹蓋 (壓鹹醖簾願簾齋廠糧糧 ) 达到更多